Intriguingly, myostatin inhibition using MYO-029 (Stamulumab) was tested in a prospective, randomized, placebo-controlled US phase I/II trial in 116 adults with muscular dystrophy such as BMD, fascioscapulohumeral muscular dystrophy (FSHD), and LGMD (Wagner et al., 2008). Here, MSTN is linked to limb-girdle muscular dystrophy.